Vanguard Group Inc. Buys 14,079 Shares of OrthoPediatrics Corp. $KIDS

Key Points

• Vanguard Group Inc. increased its stake in OrthoPediatrics Corp. by 1.5%, now holding approximately 3.86% of the company, worth $23.10 million.
• Research analysts have mixed ratings on OrthoPediatrics, with a consensus target price of $34.14 and several analysts rating it a "Buy".
• The company reported a quarterly loss with an earnings per share of ($0.11), beating expectations of ($0.17), although it had a negative net margin of 18.92%.

Vanguard Group Inc. raised its stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 1.5% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 937,969 shares of the company's stock after purchasing an additional 14,079 shares during the period. Vanguard Group Inc. owned 3.86% of OrthoPediatrics worth $23,102,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. increased its holdings in OrthoPediatrics by 3.0% in the 4th quarter. Invesco Ltd. now owns 16,363 shares of the company's stock worth $379,000 after acquiring an additional 469 shares in the last quarter. Northern Trust Corp increased its stake in shares of OrthoPediatrics by 0.3% in the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company's stock worth $4,492,000 after purchasing an additional 644 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of OrthoPediatrics by 31.1% in the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock worth $228,000 after purchasing an additional 2,338 shares in the last quarter. Barclays PLC raised its position in shares of OrthoPediatrics by 12.2% during the 4th quarter. Barclays PLC now owns 28,390 shares of the company's stock valued at $658,000 after purchasing an additional 3,092 shares during the period. Finally, Deutsche Bank AG raised its position in shares of OrthoPediatrics by 57.1% during the 4th quarter. Deutsche Bank AG now owns 14,393 shares of the company's stock valued at $334,000 after purchasing an additional 5,233 shares during the period. Institutional investors own 69.05% of the company's stock.

Insider Activity

In other news, CFO Fred Hite bought 5,076 shares of OrthoPediatrics stock in a transaction dated Thursday, August 21st. The shares were purchased at an average cost of $19.41 per share, with a total value of $98,525.16. Following the completion of the acquisition, the chief financial officer owned 213,065 shares of the company's stock, valued at $4,135,591.65. This trade represents a 2.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 31.80% of the company's stock.

OrthoPediatrics Price Performance

Shares of KIDS stock traded up $0.10 during trading hours on Wednesday, hitting $20.90. The stock had a trading volume of 128,362 shares, compared to its average volume of 165,414. OrthoPediatrics Corp. has a one year low of $16.59 and a one year high of $33.14. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. The stock's 50-day moving average price is $21.12 and its two-hundred day moving average price is $22.06. The stock has a market capitalization of $523.96 million, a price-to-earnings ratio of -11.68 and a beta of 1.06.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%.The firm had revenue of $61.08 million for the quarter, compared to analysts' expectations of $61.40 million. OrthoPediatrics has set its FY 2025 guidance at EPS. Equities analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on KIDS. Citigroup reaffirmed a "market outperform" rating on shares of OrthoPediatrics in a report on Friday, August 8th. Wall Street Zen raised OrthoPediatrics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Needham & Company LLC reissued a "buy" rating and set a $42.00 price target on shares of OrthoPediatrics in a report on Thursday, May 8th. Piper Sandler decreased their price target on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Finally, BTIG Research decreased their price target on OrthoPediatrics from $40.00 to $39.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, OrthoPediatrics presently has an average rating of "Moderate Buy" and an average price target of $34.14.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.